Abstract:Concurrent chemoradiation (CCRT) with adjuvant chemotherapy (CT) is the standard care for stage II–IV nasopharyngeal carcinoma (NPC) in NCCN guideline. CCRT has been shown to improve outcomes for stage III–IV NPC patients over radiation therapy (RT) alone, but the benefit for stage II NPC patients is controversial, especially in the era of intensity-modulated radiation therapy (IMRT). The study is to evaluate and determine the role of CCRT in stage II NPC underwent IMRT. Patients with stage II NPC (T1N1, T2N0, or T2N1; 7th ed AJCC staging) were recruited from January 2009 to June 2015 at 6 centers in China. They were randomly assigned to CCRT followed by adjuvant CT (CCRT+CT) arm or RT alone arm. All patients were treated with IMRT. The chemotherapy consisted of concurrent cisplatin (80 mg/m2 on day 1, 22, 43) during IMRT and 3 cycles of adjuvant CT with cisplatin 75mg/m2 day 1, 5-FU 750 mg/m2 24h-continuous infusion day 1-5 every 3 weeks. The primary endpoint was overall survival (OS). Secondary endpoints included locoregional failure-free survival (LRFFS), distant metastasis-free survival (DMFS), and toxicities. Survivals were calculated with Kaplan-Meier method. The differences between survivals were calculated by Log-rank test. Toxic effects were analyzed using the χ2 test. All statistical tests were two-side. A total of 168 patients were recruited and 160 were eligible for intent-for-treat analysis. 81 patients were assigned to CCRT+CT arm and 79 in RT alone arm. With a median follow-up of 61.5 months, the 3 -year and 5-year OS of all patients were 93.75% and 90.00%, respectively. The 3-year and 5-year OS of CCRT+CT arm were 93.83%, 91.36%, respectively, and 93.67% and 88.61% in RT arm, respectively. There was no significant difference in OS between two arms (P = 0.562). The 3-year and 5-year LRFFS of CCRT+CT arm were 97.53%, 96.26%, respectively, and 94.94% and 93.67% in RT arm, respectively. There was no significant difference in LRFFS between two arms (P = 0.690). The 3-year and 5-year DMFS of CCRT+CT arm were 93.82%, 93.82%, respectively, and 96.20% and 93.67% in RT arm, respectively. There was also no significant difference in DMFS between two arms (P = 0.967). There were higher local radiation acute and late side effects in the CCRT+CT arm than RT arm although not reached significant. There were significantly higher acute systemic side effects in the CCRT+CT arm, especially the incidence of grade 3-4 hematologic and gastrointestinal reactions (P =0.000). Most of locoregional recurrence (6/8, 75.00%) and distant metastases (6/7, 85.71%) occurred in the T2N1M0 group. For stage II NPC patients treated with IMRT, CCRT and adjuvant CT did not improve OS, LRFFS and DMFS. But there were more significant toxicities. Chemotherapy may not be necessary in these patients. However, further research with longer follow up is needed especially for those with T2N1 disease.

Cetuximab or Nimotuzumab Plus Intensity-Modulated Radiotherapy Versus Cisplatin Plus Intensity-Modulated Radiotherapy for Stage II-IVb Nasopharyngeal Carcinoma.

Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up

Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.

Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial

A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

An Open-Labeled, Multicentric Clinical Study of Cetuximab Combined with Intensity-Modulated Radiotherapy (IMRT) Plus Concurrent Chemotherapy in Locoregionally Advanced (LA) Nasopharyngeal Carcinoma (NPC): A 2-Year Follow-Up Report.

Long-Term Result of A Multicenter Clinical Study of Cetuximab Combined with Intensity Modulated Radiotherapy (imrt) Plus Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (Npc).

An Open, Multicenter Clinical Study on Cetuximab Combined with Intensity Modulated Radiotherapy (imrt) Plus Concurrent Chemotherapy in Nasopharyngeal Carcinoma (npc): Preliminary Report

[Concurrent Chemotherapy with Different Dose Regimens of Cisplatin for Nasopharyngeal Carcinoma Using Intensity-Modulated Radiation Therapy: a Phase II Prospective Randomized Controlled Trial].

Chemotherapy May Not Be Necessary in Stage II Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy

An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma

Effectiveness of Cetuximab in Combination with Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A 1:2 Propensity Score-matched Analysis.

Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma

Multicenter safety study on cetuximab combined with intensity modulated radiotherapy and concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma

Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study

Neoadjuvant Chemotherapy Plus Intensity-Modulated Radiotherapy Versus Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy for Ascending or Descending Types of Nasopharyngeal Carcinoma: A Retrospective Study.

Experience with Combination of Cisplatin Plus Gemcitabine Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

IMRT Combined with Concurrent Chemotherapy Plus Adjuvant Chemotherapy Versus IMRT Combined with Concurrent Chemotherapy Alone in Patients with Nasopharyngeal Carcinoma

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial

Comparison of Concurrent Chemoradiation Therapy Plus Induction Chemotherapy with Cisplatin, Fluorouracil and Docetaxel Versus Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma

Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study.